A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02)

R E Drzymala; T H Wasserman; M Won; E Shaw; A J Cmelak; J Loeffler; L Souhami; Radiation Therapy Oncology Group

doi:10.1016/j.radonc.2008.02.006

A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02)

Radiother Oncol. 2008 Apr;87(1):89-92. doi: 10.1016/j.radonc.2008.02.006. Epub 2008 Mar 14.

Authors

R E Drzymala¹, T H Wasserman, M Won, E Shaw, A J Cmelak, J Loeffler, L Souhami; Radiation Therapy Oncology Group

Affiliation

¹ Department of Radiation Oncology, Washington University Medical Center, St. Louis, MO 63110, USA. rdrzymala@radonc.wustl.edu

PMID: 18342381
DOI: 10.1016/j.radonc.2008.02.006

Abstract

RTOG 95-02 assessed patient tolerance to hypoxic cell radiosensitizer, etanidazole (SR-2508), combined with radiosurgery. Patients had primary or metastatic brain tumors and previously localized or whole brain irradiation. The toxicity is reported in three groups of patients according to the tumor size. Etanidazole doses of 12g/m2 combined with radiosurgery were well tolerated.

Publication types

Clinical Trial, Phase I

MeSH terms

Adult
Brain Neoplasms / radiotherapy*
Brain Neoplasms / secondary
Brain Neoplasms / surgery*
Combined Modality Therapy
Etanidazole / therapeutic use*
Humans
Neoplasm Recurrence, Local
Radiation-Sensitizing Agents / therapeutic use*
Radiosurgery / methods*
Radiotherapy Dosage
Survival Rate
Treatment Outcome

Substances

Radiation-Sensitizing Agents
Etanidazole